Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INDIA GLOBALIZATION CAPITAL, INC.

(IGC)
SummaryChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

India Globalization Capital : IGC Receives New Patent from U.S. Patent Office to Treat Cachexia and Eating Disorders in Humans and Veterinary Animals

03/26/2020 | 07:31pm EDT

India Globalization Capital, Inc. (the “Company”) (NYSE: IGC) recently received notification that on March 24, 2020, the United States Patent and Trademark Office (“USPTO”) issued a method and composition patent (#10,596,159 B2) for the Company’s cannabinoid formulation for the treatment of cachexia and eating disorders in humans and veterinary animals. IGC filed this application for its IGC-504 formulation (#15/751,901) on August 11, 2016. A public copy of the patent is available on the USPTO website.

A patent for an invention is the grant of a property right to the inventor, issued by the USPTO. Generally, the term of a new patent is 20 years from the date on which the application for the patent was filed in the United States or, in special cases, from the date an earlier related application was filed, subject to the payment of maintenance fees. U.S. patent grants are effective only within the United States, U.S. territories, and U.S. possessions.

Forward-looking Statements:

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on IGC’s expectations and are subject to a number of risks and uncertainties, certain of which are beyond IGC’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, worsening of the COVID-19 outbreak in China, the U.S., and other parts of the world, the prolonged continuation of travel restrictions related to the outbreak, continued disruption of the Hong Kong economy, competitive conditions in the industries in which IGC operates, failure to meet operational goals and/or revenue and profit targets of products in various stages of production and commercialization, failure to commercialize one or more of the products or technologies of IGC, including any products or patented formulations identified herein, any changes in federal, state, or local law applicable to our businesses and the locations where we operate, general economic, political, and health and welfare conditions that are less favorable than expected, the Federal Food and Drug Administration’s (FDA) general position regarding hemp-based and related products in particular, and other factors, many of which are discussed in our SEC filings. The Risk Factors identified in the Company’s annual report, filed on Form 10-K with the SEC on June 14, 2019, and in the Company’s quarterly reports, filed on Form 10-Q with the SEC on November 5, 2019 and February 10, 2020, are incorporated herein by reference. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will in fact occur.

About IGC:

IGC has two lines of business: infrastructure and hemp-derived medical cannabis/industrial hemp. The company is based in Maryland, U.S.A. Our website: www.igcinc.us.Twitter @IGCIR


ę Business Wire 2020
All news about INDIA GLOBALIZATION CAPITAL, INC.
07/22INDIA GLOBALIZATION CAPITAL : Issued US Patent for Alzheimer's Disease Treatment..
MT
07/22INDIA GLOBALIZATION CAPITAL : IGC Announces Issuance of Patent for the Treatment..
BU
07/22India Globalization Capital, Inc Announces Issuance of Patent for the Treatme..
CI
06/23INDIA GLOBALIZATION CAPITAL : IGC Completes the Final Cohort of Its Phase 1 Clin..
BU
06/23India Globalization Capital, Inc. Completes the Final Cohort of its Phase 1 C..
CI
06/14INDIA GLOBALIZATION CAPITAL : IGC Reports Financial Results for the Fiscal Year ..
BU
06/14India Globalization Capital, Inc. Announces Consolidated Earnings Results for..
CI
06/14INDIA GLOBALIZATION CAPITAL : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ..
AQ
06/07INDIA GLOBALIZATION CAPITAL : IGC Completes Cohort 2 of its Phase 1 THC-Based Cl..
BU
06/07IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s..
CI
More news
Financials (USD)
Sales 2021 0,90 M - -
Net income 2021 -8,81 M - -
Net cash 2021 13,6 M - -
P/E ratio 2021 -8,53x
Yield 2021 -
Capitalization 90,9 M 90,9 M -
EV / Sales 2020 1,85x
EV / Sales 2021 75,3x
Nbr of Employees 50
Free-Float 72,3%
Chart INDIA GLOBALIZATION CAPITAL, INC.
Duration : Period :
India Globalization Capital, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INDIA GLOBALIZATION CAPITAL, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Managers and Directors
Ram Mukunda President, Chief Executive Officer & Director
Claudia Grimaldi Principal Financial Officer & Vice President
Richard K. Prins Chairman
Jagadeesh Rao Chief Scientific Officer
Gutierrez de Pi˝eres Head-Research
Sector and Competitors